Department of Anesthesiology, Tufts Medical Center, Boston, MA.
Department of Anesthesiology and Pain Medicine, University of Washington Medical Center, Seattle, WA.
J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1681-1687. doi: 10.1053/j.jvca.2019.12.044. Epub 2020 Jan 25.
Percutaneous edge-to-edge repair of the mitral valve with the MitraClip device has been shown to serve as a safe and effective treatment for severe mitral regurgitation in the high-risk surgical population. Although the device originally was designed for the reduction of degenerative mitral regurgitation resulting from primary leaflet abnormalities, numerous studies have included patients with functional mitral regurgitation from annular or ventricular distortion. Two recent landmark studies examined the use of the MitraClip device for functional mitral regurgitation treatment and found drastically opposing results. Data reconciliation by others has suggested only a subset of those with functional mitral regurgitation may benefit from this treatment. Herein 2 seemingly similar cases to illustrate the subtle differences in patient selection that eventually may change the clinical outcome for this procedure are presented.
经皮缘对缘二尖瓣修复术(MitraClip)已被证明是高危手术人群中治疗严重二尖瓣反流的一种安全有效的方法。虽然该设备最初是为减少因原发性瓣叶异常引起的退行性二尖瓣反流而设计的,但许多研究都包括了因瓣环或心室变形而导致的功能性二尖瓣反流患者。最近的两项具有里程碑意义的研究调查了 MitraClip 设备在功能性二尖瓣反流治疗中的应用,发现结果截然不同。其他人的数据协调表明,只有一部分功能性二尖瓣反流患者可能从这种治疗中受益。本文介绍了 2 个看似相似的病例,以说明患者选择的细微差异,这些差异最终可能改变该手术的临床结果。